Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
International Journal of Clinical Pharmacy
|
February 7, 2020
Follow up survey for implementation of fixed-dosing of monoclonal antibodies
Kimberley M Heinhuis, Jos H Beijnen, Jeroen J M A Hendrikx
International Journal of Clinical Pharmacy
|
September 10, 2020
A cost analysis study of the implementation of fixed-dosing of monoclonal antibodies in the Netherlands Cancer Institute
Kimberley M Heinhuis, Hannerieke J Barkman, Jos H Beijnen, et al.
Cancers
|
August 19, 2020
Neoadjuvant Systemic Treatment of Primary Angiosarcoma
Kimberley M Heinhuis, Nikki S IJzerman, Winette T A van der Graaf, et al.
Plos One
|
August 8, 2015
A Human Cell Line Model for Interferon-α Driven Dendritic Cell Differentiation
Jurjen M Ruben, Lindy L Visser, Kimberley M Heinhuis, et al.
BMJ Open
|
September 11, 2020
PropAngio study protocol: a neoadjuvant trial on the efficacy of propranolol monotherapy in cutaneous angiosarcoma-a proof of principle study
Kimberley M Heinhuis, Nikki S IJzerman, Anne Miek Koenen, et al.
Cancers
|
May 31, 2020
RNA-Sequencing of Tumor-Educated Platelets, a Novel Biomarker for Blood-Based Sarcoma Diagnostics
Kimberley M Heinhuis, Sjors G J G In 't Veld, Govert Dwarshuis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 7, 2024
Propranolol monotherapy in angiosarcoma - A window-of-opportunity study (PropAngio)
Alaa Embaby, Kimberley M Heinhuis, Nikki S IJzerman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 7, 2021
Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors
Sylvie Rottey, Jeffrey Clarke, Kyaw Aung, et al.
JAMA Oncology
|
November 8, 2019
Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial
Kimberley M Heinhuis, Matteo Carlino, Markus Joerger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 5, 2020
OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors
Martin Gutierrez, Victor Moreno, Kimberley M Heinhuis, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
International Journal of Clinical Pharmacy
|
February 7, 2020
Follow up survey for implementation of fixed-dosing of monoclonal antibodies
Kimberley M Heinhuis, Jos H Beijnen, Jeroen J M A Hendrikx
International Journal of Clinical Pharmacy
|
September 10, 2020
A cost analysis study of the implementation of fixed-dosing of monoclonal antibodies in the Netherlands Cancer Institute
Kimberley M Heinhuis, Hannerieke J Barkman, Jos H Beijnen, et al.
Cancers
|
August 19, 2020
Neoadjuvant Systemic Treatment of Primary Angiosarcoma
Kimberley M Heinhuis, Nikki S IJzerman, Winette T A van der Graaf, et al.
Plos One
|
August 8, 2015
A Human Cell Line Model for Interferon-α Driven Dendritic Cell Differentiation
Jurjen M Ruben, Lindy L Visser, Kimberley M Heinhuis, et al.
BMJ Open
|
September 11, 2020
PropAngio study protocol: a neoadjuvant trial on the efficacy of propranolol monotherapy in cutaneous angiosarcoma-a proof of principle study
Kimberley M Heinhuis, Nikki S IJzerman, Anne Miek Koenen, et al.
Cancers
|
May 31, 2020
RNA-Sequencing of Tumor-Educated Platelets, a Novel Biomarker for Blood-Based Sarcoma Diagnostics
Kimberley M Heinhuis, Sjors G J G In 't Veld, Govert Dwarshuis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 7, 2024
Propranolol monotherapy in angiosarcoma - A window-of-opportunity study (PropAngio)
Alaa Embaby, Kimberley M Heinhuis, Nikki S IJzerman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 7, 2021
Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors
Sylvie Rottey, Jeffrey Clarke, Kyaw Aung, et al.
JAMA Oncology
|
November 8, 2019
Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial
Kimberley M Heinhuis, Matteo Carlino, Markus Joerger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 5, 2020
OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors
Martin Gutierrez, Victor Moreno, Kimberley M Heinhuis, et al.
Page
of 2